ReviewCardiac failure review2026
Integrated Cardio-oncology Service.
Review in Cardiac failure review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer and cardiovascular disease increasingly intersect in clinical practice. An integrated cardio-oncology service is a coordinated, multidisciplinary programme that embeds cardiovascular risk assessment, on-treatment surveillance and post-treatment follow-up within routine cancer care, supported by shared protocols and decision-making. The aim of such services is to maintain the delivery of best-practice cancer therapy while preventing and treating cardiovascular toxicity. This review distils pragmatic, transferable elements for cardiac and oncology teams: a unified programme with risk-based streaming; nurse-enabled triage and surveillance; pharmacist-led drug-drug interaction stewardship and medication optimisation; fast-track imaging and cardiology access; and clear triggers for escalation that minimise unnecessary cancer therapy interruption. The goal for this review is to provide a pragmatic blueprint for such services, illustrated by international models and our Newcastle bench-to-bedside experience.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.